Introduction
report worse physical and mental health as well as being more likely to be unemployed due to health reasons than their urban counterparts [14] [15] [16] . They also face several challenges in accessing care due to scarce medical resources and the need to travel longer distances to visit doctors and receive care [17] [18] [19] . Rural residence and travel also affect the treatment choices patients with cancer make and the follow-up care they receive post-treatment [15, 17, 20] . Moreover, poverty levels are higher in rural counties, and many rural residents are self-employed or employed in small businesses facing challenges related to paying high insurance premiums and OOP expenses [17] . Survivors residing in rural areas were more likely to forego health care because of cost, particularly those who were older than 65 years of age [21] . In a survey of survivors in Ohio, about 25% of rural survivors reported needs related to paying medical bills and 21% needs related to health insurance compared to less than 18% and 13% of the urban survivors, respectively [22] . Canadian rural cancer survivors were more likely to report travel costs and child care costs as important in treatment decisions compared to urban survivors [23] . Currently, we do not know what OOP costs are incurred by rural cancer survivors for their long-term well-being, how burdensome these OOP costs may be, and what factors may lead to higher OOP costs and burden. Understanding more about these costs will allow for the design of interventions to manage such expenses and prevent rural cancer survivors from foregoing the care they need.
The objective of this study was to report the OOP costs of rural breast cancer survivors who participated in the Rural Breast Cancer Survivor Intervention (RBCS) trial [24] [25] [26] . This trial tested the dissemination of an efficacious survivor-centered, self-management intervention addressing cancer treatment late effects, surveillance recommendations, healthy living after cancer, psychosocial concerns, and family, work, and insurance challenges among rural breast cancer survivors. Data from this trial allowed the unique opportunity to report on the OOP expenses of these rural survivors, an underserved population of which we know little about survivorship need and economic burden. We report OOP costs as well as OOP cost burden (i.e., the proportion of income spent on cancer-related OOP costs). We further explore demographic, socioeconomic, and cancer characteristics that may be associated with OOP costs and OOP cost burden.
Methods
This study was approved by Institutional Review Boards of the University of Alabama at Birmingham and the Florida Department of Health. Participants were women living in rural Florida diagnosed with Stage 0-III breast cancer, within the first three years after completing primary cancer treatment, at least 21 years of age, and with telephone or cell phone access. Rural eligibility was established based on residence in one of 33 Florida rural counties, or in a rural pocket of one of 34 Florida urban counties [27] .
A total of 432 RBCS participants were randomized to either the Early Education and Support intervention group or the Delayed Education and Support intervention group. The RBCS four components included one intake assessment; three education and support sessions; one follow-up education and support session; and six support calls. The early and delayed interventions had the same components, but participants in the delayed group received the support calls in the first 6 months after enrollment, and the education and support sessions at month 7.
Measures
OOP costs incurred by survivors for cancer-related medical care and other care to maintain or improve well-being were collected using the Work and Finances Inventory (WFI) questionnaire. The WFI is a descriptive 46-item survey, adapted and modified from Given et al. [28] , with items asking about OOP costs incurred since the end of primary breast cancer treatment (baseline assessment), or since the last time the participant was surveyed (follow-up assessments). Specifically, participants were asked about breast cancer-related expenses that they, or their relative or any family member, spent OOP, excluding money repaid by insurance (whether they incurred any and, if so, how much in US dollars). The WFI also includes questions related to changes in family income and health insurance, work, and other economic events (e.g., filing for bankruptcy, unemployment, and loss of savings).
To assess participants' characteristics and treatment, we used the Breast Cancer Survivor Socio-demographic and Treatment Survey which includes questions on sociodemographics (i.e., age, race, ethnicity, education level, marital status, type of health insurance, work status, and number of people living in the home) and questions on breast cancer treatment (i.e., months since diagnosis and months since end of treatment, type of breast cancer surgery, radiation therapy, chemotherapy, hormonal therapy, and/or anti-HER2 therapy) [7, 8, 29] . In addition, we measured depressive symptoms using the Centers for Epidemiologic Studies Depression Scale (CES-D) [30] . Scores ≥16 suggest clinically significant levels of psychological distress or depression [31] .
Data were collected at baseline and at 3-month intervals for a total of five assessment points over 12 months. OOP costs were grouped as follows: 
Analysis
We used a repeated measure model fitted with generalized linear mixed methods and a gamma distribution to explore which factors were associated with OOP costs across all time points [32] . These included assessment time, demographics (i.e., age, marital status, race), socioeconomic status (i.e., education, employment, income, self-reported income decrease since end of treatment, health insurance), and cancer factors (i.e., time since end of treatment, cancer treatment, use of prior or concurrent support services such as cancer support groups, counseling, or support websites). Predicted means were calculated for those factors significantly associated with OOP costs. The effect of the group assignment (Early vs. Delayed Education and Support) on OOP cost was examined as part of the main intervention evaluation. No relevant group assignment effect on OOP costs was found and, therefore, the combined sample was used in the analysis presented here.
At each assessment point, we computed OOP burden as the percent of monthly income spent on OOP cancerrelated costs. To explore which factors were associated with OOP burden, we used a repeated measure model fitted with generalized linear mixed methods and a beta distribution with logit link using the same predictors listed above. Predicted means were calculated for those factors significantly associated with OOP burden.
Six months after enrollment, 361 participants were retained (16% attrition). Due to an association between baseline self-reported mental health and dropout risk [24] , the impact of missing data on our analysis was mitigated by using linear mixed models and including an indicator for depression (baseline score for the CES-D scale ≥16). Significance was held at the traditional 0.05 level. No correction for multiple testing was applied due to the exploratory rather than confirmatory nature of the analyses. All analyses were conducted using SAS v9.4 (SAS Institute Inc., 2013).
Results
Almost half of the 432 rural breast cancer survivors in this study were 65 years old and older, and the majority was married or living with a partner and Caucasian (Table 1) . About 25% had low education (high school or less), 45.4% were retired, and 34.8% had a family income of $40,000 or less, but most (94.4%) had health insurance, usually Medicare. About 80% were 12 months or more past the end of treatment with 23.4% being 25 months or more past that time point. The majority received surgery with radiation or surgery with chemotherapy and radiation and were on hormonal treatment.
OOP costs per month measured at baseline, representing monthly costs since the end of treatment, were on average $232.7 (median $95.6) (Fig. 1) . The mean and median OOP costs declined from baseline to the next assessment point but remained constant after that (Fig. 1) . At each assessment point, between 87.9% and 93.1% of participants reported costs for medical care, with means of $194.7 at baseline and between $129 to $147 in the rest of the assessments (Table 2 ). Between 18.6% and 27.7% reported OOP costs for counseling and health maintenance, with means of $78.1 at baseline and between $88.4 to $167.2 in the other assessments (Table 2) . Between 2.1% and 23.0% reported OOP costs for side effect management, with means of $17.5 at baseline and between $38.5 to $58.6 in the follow-up assessments (Table 2) . Lastly, between 15.4% and 20.9% reported costs for home maintenance, with means of $111.7 at baseline and between $141.2 to $185.6 in the rest of the assessments ( Table 2) .
The predicted mean OOP monthly costs were significantly higher at baseline ($222.5) than at the other assessment points (Fig. 2) . Compared to Month 12, the mean ratio for OOP costs at baseline was 1.37 (CI: 1.13-1.66, Table 3 ). Across all assessments, participants who were younger than 65, had income decreases since diagnosis, were within 1 year of diagnosis, and used other supportive services had higher OOP costs ( Fig. 2 and Table 3 ). The lowest predicted mean OOP cost was for participants who were more than 24 months from diagnosis ($141.7) and the highest was for OOP costs at baseline ($222.5), for survivors who were less than 12 months from diagnosis ($220.1) or younger than 65 ($219.3) (Fig. 2) .
The predicted mean OOP burden (i.e., OOP costs as a percentage of income) was higher at baseline than in the other assessments (P = 0.007 Table 3 ). The predicted mean OOP burden was 9.8% at baseline, and between 7% and 8% in the other assessment months (Fig. 3) . Across all assessments, younger participants, those with lower income, reporting income decreases since diagnosis, or using support services, had higher OOP burden (Table 3 ). Survivors with disability had lower burden than working survivors (Table 3 ). The lowest predicted OOP burden was for women on disability (5.1%), and the highest was for participants with incomes below $20,000 (13.0%) (Fig. 3) .
Discussion
Out-of-pocket costs after completing primary cancer treatment remained a substantial portion of the income of rural breast cancer survivors. Most of these costs were for medical care, including for hospital bills and medications, and declined over time as women progressed from diagnosis and into survivorship. However, these expenses are large and represent almost 13% of income for women with incomes below $20,000. These findings lead to a Figure 1 . Mean, median, and bootstrap 95% confidence intervals for total monthly out-of-pocket (OOP) costs reported by study participants over the study period. Monthly cost in 2015 dollars.
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strong rationale for developing and testing interventions to address financial burden.
Cancer affects quality and quantity of life, and also the economic well-being of survivors [5, [33] [34] [35] [36] [37] [38] . The recent literature refers to patients' costs as another side effect of cancer treatment, namely its "financial toxicity." [39] [40] [41] [42] [43] The Institute of Medicine identifies, as a tenet of high-quality cancer care, the delivery to patients and families of "understandable information" including information on costs of cancer care [44] . Similarly, we believe survivors should be aware of the costs to be incurred in survivorship. At a minimum, we should understand whether these costs act as barriers to obtaining recommended and needed care.
Our results are consistent with previous work showing that the financial toxicity of cancer does not end once primary treatment is over. Breast cancer survivors from Florida urban areas who had finished treatment and were within 2 years of diagnosis spent on average more than $300 per month in the period after diagnosis [7] . This represented up to 30% of income for women with incomes below $20,000 [7] . Among the Florida rural breast cancer survivors analyzed here, survivors spent OOP for cancerrelated expenses on average more than $200 per month after treatment completion or up to about 13% of income for women with incomes below $20,000. The OOP costs reported in these two studies are somewhat different despite survivors being from the same state and responding to the same survey tool. However, in the first study, women were closer to diagnosis, and this may in part explain the difference. The lower costs of rural survivors may also be due to differences in healthcare-seeking behavior. Given the longer distances to treatment centers, rural survivors may choose to obtain less care and, as a result, incur lower costs [17] [18] [19] . Moreover, given also work challenges, rural breast cancer survivors may not take time off needed to travel for follow-up cancer surveillance appointments [45] . In one study, rural survivors were more likely to forgo medical and other care because of cost, especially older survivors [21] . However, despite the lower level, OOP costs for rural survivors represent a substantial portion of income, especially for those more vulnerable. Out-of-Pockets Costs of Rural Survivors M. Pisu et al.
The rural breast cancer survivors most burdened by cancer costs were younger and low-income survivors. These results are in line with others who found that these groups, as well as women of minority backgrounds, are more likely to report worse financial-related outcomes. For example, they are more likely to report a financial decline since diagnosis [38] , debt and major privations such as less medical care or medication, no insurance, or utilities turned off because of missed bill payments [38] , OOP cost burdens for medical care of 20% of income or higher [2] , higher likelihood of financial hardship [36, 46] , financial problems related to cancer [12] , or higher economic hardship in survivorship such as difficulty living on household income [47] . Therefore, understanding how support interventions may help containing the cancer cost burden is especially important for these most vulnerable groups.
Currently, to our knowledge, there are no effective interventions to address cost burden in cancer survivors. A recent systematic review summarized the rapidly evolving field of financial toxicity directly related to the continued and escalating costs of cancer care [48] . The authors identified 45 relevant articles among 676 recent studies: Of these, none contained specific interventions to reduce the problem. However, the authors developed a multidimensional construct of financial hardship based on a typology of three related areas: material conditions (i.e., OOP costs, missed work days, reduced or lost income, and medical debt and bankruptcy); psychological response (i.e., distress related to cancer care costs and concern about wages and income to meet additional expenses); and coping behaviors (i.e., skipping or reducing medications, missing or delaying follow-up cancer surveillance visits). Given this typology, future interventions may be directed toward understanding the material conditions, developing specific psychological response interventions, and evaluating the related coping behaviors. Data similar to those in our study are important to inform on material conditions related to patient/survivor-reported cancer OOP costs for the period after primary treatment, and to identify the survivors most in need of intervention. Of interest is not only the OOP cost amounts, but what rural breast cancer survivors spent on: while medical care With continued cost shifting to survivors through higher insurance premiums and deductibles, and the long-term effects of cancer that require expenses in addition to medical care costs, strong assessment and ongoing surveillance of OOP costs and the multiple domains of hardship are warranted to ensure that survivors have access to the resources they need to maintain their health and well-being. There are some limitations to consider. First, OOP costs were self-reported and were not systematically verified. However, the data collectors encouraged participants to have receipts and bills on hand to jog their memory about expenses incurred. Second, we may have not included some costs that survivors considered related to cancer. For example, a group of survivors reported expenses for gifts to people who helped them as costs they would not have had if they were not diagnosed with cancer [49, 50] . Furthermore, we did not include costs associated with missing work due to pursuing medical care and other services to maintain health, as survivors may lose hourly wages. Third, we did not include a control group of participants without cancer; thus, we are not certain that the reported expenses are cancer related even though we asked participants to report breast cancer-related expenses.
However, other studies have shown higher OOP costs for patients with cancer compared to people with other chronic conditions [2] . Furthermore, we are not certain about the costs that may have resulted from the interventions delivered in this study which educated women about the need for follow-up care and the management of long-term effects of cancer. Our participants may have incurred higher expenses than survivors not exposed to such education. Fourth, our participants may not represent rural cancer survivors in the United States or in Florida. However, by using a population-based sampling we were able to recruit rural women living in all known rural counties in the State of Florida as well as those living in rural pockets of urban counties. All 432 participants indicated residence in one of 63 of the 67 counties in Florida.
Conclusion
In this population of rural breast cancer survivors, the out-of-pocket costs of cancer-related care persisted in the years post-treatment and burdened especially younger and Research should continue to investigate the impact that costs of cancer may have on the ability of rural cancer survivors to afford follow-up care and other services needed to optimize their well-being, and develop interventions with a potential to address, at least in part, the long-term economic burden of cancer.
